Sanofi and Regeneron Report Phase 3 BOREAS Results for Dupixent in COPD

Sanofi and Regeneron today announced results from the Phase 3 BOREAS trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe COPD with type 2 inflammation who are former smokers. The trial met its primary endpoint, demonstrating a significant reduction in moderate or severe COPD exacerbations compared to placebo. These results led to FDA approval of Dupixent for COPD.